Concorde Asset Management’s Gilead Sciences GILD Stock Holding History

Concorde Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Sell	1,653 -39	-2%	-$5.14K	0.12%	136
2026 Q1	$236K	Sell	1,692 -228	-12%	-$31.9K	0.12%	170
2025 Q4	$236K	Sell	1,920 -654	-25%	-$79.5K	0.09%	201
2025 Q3	$283K	Buy	+2,574	New	+$293K	0.12%	165
2025 Q1	$268K	Sell	2,537 -42	-2%	-$4.33K	0.14%	128
2024 Q4	$238K	Buy	2,579 +59	+2%	+$5.31K	0.12%	154
2024 Q3	$211K	Buy	+2,520	New	+$192K	0.12%	159
2021 Q2	–	Sell	-3,248	Closed	-$212K	–	207
2021 Q1	$212K	Buy	+3,248	New	+$209K	0.12%	195
2016 Q3	–	Sell	-4,708	Closed	-$392K	–	128
2016 Q2	$392K	Buy	4,708 +1,053	+29%	+$93.5K	0.39%	61
2016 Q1	$338K	Buy	3,655 +435	+14%	+$39.2K	0.39%	66
2015 Q4	$325K	Buy	+3,220	New	+$335K	0.36%	69
2015 Q3	–	Sell	-4,923	Closed	-$576K	–	100
2015 Q2	$576K	Buy	4,923 +1,072	+28%	+$117K	0.73%	35
2015 Q1	$378K	Buy	3,851 +1,428	+59%	+$145K	0.43%	61
2014 Q4	$242K	Buy	+2,423	New	+$251K	0.3%	76

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Concorde Asset Management's GILD Position: Q2 2026 in Review

Concorde Asset Management reduced its Gilead Sciences (GILD) stake by 2.3% in Q2 2026, selling an estimated $5.14K and leaving 1,653 shares worth $209K. The position accounts for 0.12% of the portfolio, ranked #136.

Concorde Asset Management first reported a position in GILD in Q4 2014 and has held it in 14 quarters since. The position peaked at $576K in Q2 2015. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Concorde Asset Management held 1,653 shares of Gilead Sciences worth $209K as of Q2 2026.
Concorde Asset Management sold 39 Gilead Sciences shares in Q2 2026, an estimated $5.14K.
Gilead Sciences made up 0.12% of Concorde Asset Management's portfolio in Q2 2026, its #136 holding.
Concorde Asset Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 14 quarters since.
Concorde Asset Management's Gilead Sciences position peaked at $576K in Q2 2015.
2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Concorde Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.